FDA Approves Genentech's Vabysmo for the Treatment of Retinal Vein Occlusion (RVO) Seite 1
27.10.2023 - Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Vabysmo (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO). RVO ... Seite 1
Source: wallstreet-online.de